Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP thoracic paravertebral injection for thoracic herpes zoster pain
ChiCTR2400087248Phase 2Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of platelet-rich plasma and famciclovir in herpes zoster (HZ) and postherpetic neuralgia (PHN) (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: Incidence rate of postherpetic neuralgia at 12 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
platelet-rich plasmafamciclovir
03
Conditions
herpes zoster (HZ)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ChiCTR2400087248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087248.